A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.
Researchers from the University of California San Francisco developed and applied a computational drug repurposing algorithm to 1,300 FDA-approved drugs or previously investigated compounds with the aim of identifying drugs that could potentially be repurposed.
Here are three notes from the study:
- Two drugs — the breast cancer drug letrozole, and the colon and lung cancer drug irinotecan — were identified as possible options as they target Alzheimer’s-related gene expression changes.
- When combined, the drugs seemed to slow or reverse Alzheimer’s disease symptoms in mice.
- “These results highlight the promise of cell-type-directed combination therapies in addressing multifactorial diseases like Alzheimer’s disease and lay the groundwork for precision medicine tailored to patient-specific transcriptomic and clinical profiles,” the study authors wrote.
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
